The effect of changing thienopyridine drugs on platelet aggregation for patients with acute and elective stent placement in coronary artery
Not Applicable
- Conditions
- Ischemic heart diseases with PCI
- Registration Number
- JPRN-UMIN000015122
- Lead Sponsor
- Kurume University Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 150
Inclusion Criteria
Not provided
Exclusion Criteria
(1) Patients with tendency or factor of bleeding (2) Patients with severe hepatic dysfunction (3) Patients with severe renal dysfunction (4) Patients under antihypertensive therapy or with poor control of blood pressure (5) Patients with a history of cerebral infarction or transient cerebral ischemia (6) Patients with hypersensitivity to thienopyridine (7) Patients receiving thienopyridine within 30 days of the initial dose (8) Patients who have difficulties in participation in this study by the investigator's judgment
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method PRU value at 6 weeks after the initial dose
- Secondary Outcome Measures
Name Time Method PRU value by genetic polymorphism of the CYP2C19 gene Frequency of hemorrhagic adverse events during the dosing period